Chimeric antigen receptor (CAR)-NK cell therapy in gastrointestinal (GI) cancers; a new arena

Area of Science:

• Immunology
• Oncology
• Biotechnology

Background:

• Tumor microenvironment (TME) complexity and immune escape are key challenges in malignancy treatment.
• Limited success of T cell immunotherapy necessitates advanced strategies like natural killer (NK) cell-based therapies.
• NK cells are crucial innate immune cells combating malignancies, particularly within the TME of gastrointestinal (GI) cancers.

Purpose of the Study:

• To examine the advancements in therapeutic capabilities of chimeric antigen receptor (CAR)-engineered NK cells for GI cancer immunotherapy.
• To highlight the potential of CAR-NK cells as a novel treatment modality for GI malignancies.

Main Methods:

• Genetic engineering of NK cells to express CARs targeting tumor-associated antigens (TAAs).
• Evaluation of CAR-NK cell properties including safety, cytotoxic function, proliferation, survival, and tumor infiltration.
• Assessment of CAR-NK cell efficacy in overcoming TME resistance and promoting anti-tumor responses.

Main Results:

• CAR-NK cells demonstrate enhanced safety profiles, with minimal risk of cytokine release syndrome (CRS) and graft-versus-host disease (GVHD).
• CAR-NK cells exhibit versatile mechanisms for stimulating cytotoxic function and are suitable for "off-the-shelf" manufacturing.
• Genetically modified CAR-NK cells can effectively target TAAs, enhance anti-tumor immunosurveillance, and overcome TME-mediated resistance.

Conclusions:

• CAR-NK cell therapy represents a promising and safer alternative to CAR-T cell therapy for GI cancers.
• The adaptability and inherent safety of CAR-NK cells position them as a significant advancement in cancer immunotherapy.
• Further research into CAR-NK cell applications holds potential for improved treatment outcomes in GI cancer patients.